Evolus (EOLS) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase summary

Company overview and market positioning

• Focuses exclusively on performance beauty, targeting the intersection of healthcare and beauty with a cash pay model and no therapeutic products.

• Flagship product Jeuveau is a neurotoxin for cosmetic use, holding 13% U.S. market share and ranking third among five competitors.

• Expanded addressable market by 78% to $6 billion with the addition of a hyaluronic acid dermal filler line, with FDA submission in June and commercial launch expected next year.

• Differentiates through value-added solutions for practices and a strong focus on millennial consumers, who drive category growth.

Consumer trends and marketing strategy

• Millennials are twice as likely as previous generations to use neurotoxins, fueling 10%-15% annual category growth over the past five years.

• Over 50% of new loyalty program members are millennials, reflecting successful targeting of younger consumers.

• Marketing emphasizes beauty over medical procedure, appealing to younger demographics and new entrants.

• Growth is driven by both new patient acquisition and switching from competitors, especially from Botox.

Product and service differentiation

• Only cash pay-focused neurotoxin provider, allowing for flexible pricing and value-added services not available to competitors.

• Loyalty program (Evolux) offers tiered discounts, co-branded media campaigns, and training for providers.

• Consumer loyalty program provides $40 off per treatment, the highest and most consistent offer in the market.

• Co-branded media and training programs enhance practice growth and product adoption.